 Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin. The post Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin appeared first on Investors Business Daily. 